Home/Pipeline/Retatrutide

Retatrutide

Obesity

Phase 3Ongoing (TRIUMPH)

Key Facts

Indication

Obesity

Phase

Phase 3

Status

Ongoing (TRIUMPH)

Company

Eli Lilly

About Eli Lilly

Eli Lilly is a mission-driven pharmaceutical giant focused on discovering, developing, and commercializing medicines that address significant unmet medical needs in core therapeutic areas. The company has achieved monumental commercial success with recent blockbusters in diabetes (Mounjaro®/tirzepatide) and obesity (Zepbound®/tirzepatide), while also making historic strides in Alzheimer's disease with the approval of donanemab. Its strategy leverages deep scientific expertise across multiple modalities, a massive and diversified clinical pipeline, and a forward-looking commercial approach that integrates drug delivery with patient support services to secure long-term growth.

View full company profile

Therapeutic Areas

Diabetes Obesity Oncology Immunology Neuroscience Dermatology Autoimmune Sleep Disorders Migraine

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
RGT-075	Regor Therapeutics	Phase 2b	Active
Anti‑Obesity Oral Drug	Premas Biotech	Phase 1	Active
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active